Shanghai Henlius Biotech announced a $122.5 million agreement to acquire greater China rights for two anti-TPOR-2 antibodies from Chiome Bioscience of Japan . As part of the package, Henlius has an option for global rights to the antibodies. LIV-2008/2008b are pre-clinical mAbs that target cell surface antigen TROP-2 (Trophoblast cell-surface antigen 2), which is overexpressed in breast, colon, lung and other types of solid cancers. Henlius is the main biotech subsidiary of Fosun Pharma. More details.... Stock Symbol: (HK: 2696) Share this with colleagues: // //